# CEL Sci Corp: financial statements, quarterly

CVM · NYSE · CIK 725363 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Sep 30

Pages: [Overview](/companies/cvm.md) · [Financials](/companies/cvm/financials.md) · [Filings](/companies/cvm/filings.md) · [Insiders](/companies/cvm/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cvm/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $k | [5,268 d](/filings/0001654954-25-000288.md) | [4,353](/filings/0001654954-25-001578.md) | [4,629](/filings/0001654954-25-005606.md) | [4,703](/filings/0001654954-25-009568.md) | [4,477 d](/filings/0001654954-25-014303.md) | [4,430](/filings/0001654954-26-001319.md) | [4,014](/filings/0001654954-26-005005.md) | [3,740](/filings/0001654954-26-007657.md) | [3,703 d](/filings/0001654954-25-014303.md) | [3,677](/filings/0001654954-26-001319.md) | [3,767](/filings/0001654954-26-005005.md) | [3,650](/filings/0001654954-26-007657.md) |
| Operating income | $k | [(7,468) d](/filings/0001654954-25-000288.md) | [(6,486)](/filings/0001654954-25-001578.md) | [(7,076)](/filings/0001654954-25-005606.md) | [(6,670)](/filings/0001654954-25-009568.md) | [(6,120) d](/filings/0001654954-25-014303.md) | [(6,893)](/filings/0001654954-26-001319.md) | [(6,394)](/filings/0001654954-26-005005.md) | [(5,489)](/filings/0001654954-26-007657.md) | [(6,033) d](/filings/0001654954-25-014303.md) | [(5,369)](/filings/0001654954-26-001319.md) | [(5,326)](/filings/0001654954-26-005005.md) | [(5,557)](/filings/0001654954-26-007657.md) |
| Interest expense | $k | not reported | not reported | not reported | not reported | not reported | [170](/filings/0001654954-26-001319.md) | [178](/filings/0001654954-26-005005.md) | [172](/filings/0001654954-26-007657.md) | [129 d](/filings/0001654954-25-014303.md) | [88.0](/filings/0001654954-26-001319.md) | [117](/filings/0001654954-26-005005.md) | [111](/filings/0001654954-26-007657.md) |
| Income tax | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $k | [(7,802) d](/filings/0001654954-25-000288.md) | [(6,710)](/filings/0001654954-25-009568.md) | [(7,245)](/filings/0001654954-25-009568.md) | [(6,857)](/filings/0001654954-25-009568.md) | [(6,109) d](/filings/0001654954-25-014303.md) | [(7,073)](/filings/0001654954-26-007657.md) | [(6,572)](/filings/0001654954-26-007657.md) | [(5,665)](/filings/0001654954-26-007657.md) | [(6,101) d](/filings/0001654954-25-014303.md) | [(5,469)](/filings/0001654954-26-007657.md) | [(5,466)](/filings/0001654954-26-007657.md) | [(5,668)](/filings/0001654954-26-007657.md) |
| Diluted EPS | $ per share | not reported | [(0.14)](/filings/0001654954-25-001578.md) | [(0.14)](/filings/0001654954-25-005606.md) | [(4.18)](/filings/0001654954-25-009568.md) | not reported | [(3.25)](/filings/0001654954-26-001319.md) | [(2.33)](/filings/0001654954-26-005005.md) | [(1.36)](/filings/0001654954-26-007657.md) | not reported | [(0.68)](/filings/0001654954-26-001319.md) | [(0.67)](/filings/0001654954-26-005005.md) | [(0.47)](/filings/0001654954-26-007657.md) |
| Basic EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: not reported

## Balance sheet

| Line item | Unit | FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current assets | $m | [6.9](/filings/0001654954-25-000288.md) | [6.2](/filings/0001654954-24-001793.md) | [8.5](/filings/0001654954-24-006411.md) | [3.5](/filings/0001654954-24-010651.md) | [6.1](/filings/0001654954-25-014303.md) | [5.9](/filings/0001654954-25-001578.md) | [3.0](/filings/0001654954-25-005606.md) | [2.6](/filings/0001654954-25-009568.md) | [11.6](/filings/0001654954-26-007657.md) | [7.0](/filings/0001654954-26-001319.md) | [2.9](/filings/0001654954-26-005005.md) | [7.5](/filings/0001654954-26-007657.md) |
| Total assets | $m | [30.5](/filings/0001654954-25-000288.md) | [28.7](/filings/0001654954-24-001793.md) | [30.0](/filings/0001654954-24-006411.md) | [24.1](/filings/0001654954-24-010651.md) | [27.0](/filings/0001654954-25-014303.md) | [25.7](/filings/0001654954-25-001578.md) | [21.8](/filings/0001654954-25-005606.md) | [20.3](/filings/0001654954-25-009568.md) | [28.2](/filings/0001654954-26-007657.md) | [22.9](/filings/0001654954-26-001319.md) | [17.7](/filings/0001654954-26-005005.md) | [21.4](/filings/0001654954-26-007657.md) |
| Current liabilities | $m | [5.6](/filings/0001654954-25-000288.md) | [4.9](/filings/0001654954-24-001793.md) | [5.1](/filings/0001654954-24-006411.md) | [5.5](/filings/0001654954-24-010651.md) | [4.6](/filings/0001654954-25-014303.md) | [5.5](/filings/0001654954-25-001578.md) | [5.5](/filings/0001654954-25-005606.md) | [5.6](/filings/0001654954-25-009568.md) | [5.1](/filings/0001654954-26-007657.md) | [5.0](/filings/0001654954-26-001319.md) | [4.8](/filings/0001654954-26-005005.md) | [5.1](/filings/0001654954-26-007657.md) |
| Total liabilities | $m | [17.3](/filings/0001654954-25-000288.md) | [16.1](/filings/0001654954-24-001793.md) | [15.7](/filings/0001654954-24-006411.md) | [15.6](/filings/0001654954-24-010651.md) | [14.1](/filings/0001654954-25-014303.md) | [14.4](/filings/0001654954-25-001578.md) | [13.8](/filings/0001654954-25-005606.md) | [13.3](/filings/0001654954-25-009568.md) | [12.2](/filings/0001654954-26-007657.md) | [11.8](/filings/0001654954-26-001319.md) | [10.8](/filings/0001654954-26-005005.md) | [10.4](/filings/0001654954-26-007657.md) |
| Shareholders' equity | $m | [13.2](/filings/0001654954-25-014303.md) | [12.7](/filings/0001654954-25-009568.md) | [14.3](/filings/0001654954-25-009568.md) | [8.5](/filings/0001654954-25-009568.md) | [12.9](/filings/0001654954-26-007657.md) | [11.3](/filings/0001654954-26-007657.md) | [8.0](/filings/0001654954-26-007657.md) | [7.0](/filings/0001654954-26-007657.md) | [16.0](/filings/0001654954-26-007657.md) | [11.1](/filings/0001654954-26-007657.md) | [6.9](/filings/0001654954-26-007657.md) | [11.0](/filings/0001654954-26-007657.md) |

- Cash and equivalents: not reported
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(5,045) d](/filings/0001654954-25-000288.md) | [(4,888)](/filings/0001654954-25-001578.md) | [(4,528) d](/filings/0001654954-25-005606.md) | [(4,579) d](/filings/0001654954-25-009568.md) | [(4,817) d](/filings/0001654954-25-014303.md) | [(4,140)](/filings/0001654954-26-001319.md) | [(4,370) d](/filings/0001654954-26-005005.md) | [(3,940) d](/filings/0001654954-26-007657.md) | [(4,671) d](/filings/0001654954-25-014303.md) | [(4,022)](/filings/0001654954-26-001319.md) | [(4,022) d](/filings/0001654954-26-005005.md) | [(4,031) d](/filings/0001654954-26-007657.md) |
| Capital expenditure | $k | [0.0 d](/filings/0001654954-25-000288.md) | [51.7](/filings/0001654954-25-001578.md) | [0.0 d](/filings/0001654954-25-005606.md) | [23.5 d](/filings/0001654954-25-009568.md) | [19.8 d](/filings/0001654954-25-014303.md) | [33.0](/filings/0001654954-26-001319.md) | [0.0 d](/filings/0001654954-26-005005.md) | [0.0 d](/filings/0001654954-26-007657.md) | [5.2 d](/filings/0001654954-25-014303.md) | [0.0](/filings/0001654954-26-001319.md) | [0.0 d](/filings/0001654954-26-005005.md) | [0.0 d](/filings/0001654954-26-007657.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2022 (2021-12-31) | Q3 FY2022 (2022-06-30) | Q1 FY2023 (2022-12-31) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [43.1](/filings/0001654954-23-001725.md) | [43.2](/filings/0001654954-22-011196.md) | [44.4](/filings/0001654954-23-001725.md) | [48.5](/filings/0001654954-25-001578.md) | [52.0](/filings/0001654954-25-005606.md) | [1.8](/filings/0001654954-25-009568.md) | [2.2](/filings/0001654954-26-001319.md) | [2.8](/filings/0001654954-26-005005.md) | [4.2](/filings/0001654954-26-007657.md) | [8.0](/filings/0001654954-26-001319.md) | [8.1](/filings/0001654954-26-005005.md) | [12.1](/filings/0001654954-26-007657.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 17,588,987 at 2026-08-10, from the cover of the [10-Q filed 2026-08-14](/filings/0001654954-26-007657.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:23 ET. No prices; not investment advice.